Ipca Laboratories Ltd has has tied up with US-based Heritage Pharmaceuticals Inc for manufacture and marketing of a drug in the American markets.
Under the alliance, Ipca has received approval from US Food and Drugs Administration to manufacture and market Propranolol HCI Oral Tablets in the US market, while Heritage will market the drug.
Propranolol tablets treats cardiovascular related indications, including the management of hypertension, treatment of angina and atrial fibrillation. Propranolol had US brand and generic sales of approximately $25 million for the 12-month period ending December 31, 2007, according to IMS Health.
